Apellis Pharmaceuticals, Inc. (APLS)

Market Cap	6.02B
Revenue (ttm)	396.59M
Net Income (ttm)	-528.63M
Shares Out	120.58M
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,157,827
Open	48.84
Previous Close	48.72
Day's Range	48.62 - 50.41
52-Week Range	19.83 - 94.75
Beta	0.89
Analysts	Strong Buy
Price Target	76.24 (+52.69%)
Earnings Date	May 7, 2024

About APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 9, 2017
• Employees: 702
• Stock Exchange: NASDAQ
• Ticker Symbol: APLS

Financial Performance

In 2023, APLS's revenue was $396.59 million, an increase of 425.83% compared to the previous year's $75.42 million. Losses were -$528.63 million, -18.94% less than in 2022.

Analyst Forecast

According to 17 analysts, the average rating for APLS stock is "Strong Buy." The 12-month stock price forecast is $76.24, which is an increase of 52.69% from the latest price.

Price Target

$76.24

(52.69% upside)

Analyst Consensus: Strong Buy